Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours

This study has been completed.
INC Research
Information provided by (Responsible Party):
Philogen S.p.A. Identifier:
First received: January 27, 2010
Last updated: February 24, 2014
Last verified: February 2014